Error-Prone Candidates Vie for Somatic Mutation by Poltoratsky, Vladimir et al.
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2000/11/F27/04 $5.00
Volume 192, Number 10, November 20, 2000 F27–F30
http://www.jem.org/cgi/content/full/192/10/F27
 
Commentary
 
F27
 
Error-prone Candidates Vie for Somatic Mutation
 
By Vladimir Poltoratsky,
 
*
 
 Myron F. Goodman,
 
‡
 
 
and Matthew D. Scharff
 
*
 
From the 
 
*
 
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 
 
10461; and the 
 
‡
 
Department of Biological Sciences and Chemistry, University of Southern California, 
Los Angeles, California 90089
 
Antibodies play a major role in the resistance of higher
organisms to disease. This is made possible because mice,
humans, and other species have evolved three unusual mo-
lecular mechanisms that allow the generation of an enor-
mously diverse repertoire of antibodies from a relatively
small amount of genetic material. First, each antibody-
forming B cell assembles different combinations of variable
(V), diversity (D), and joining (J) minigenes to create an
antibody with a unique antigen-binding site. Second, to
generate the high-affinity antibodies that are required for
survival, B cells target many point mutations to the V(D)J
regions of the H and VJ region of the L chain immunoglo-
bulin (Ig) genes. Those B cells that are making higher affin-
ity antibodies are selected for further growth and differenti-
ation, resulting in the affinity maturation of the antibody
response. Third, B cells rearrange the H chain V region to
various downstream C regions that encode the different
isotypes. This makes it possible for each of the many anti-
gen-binding sites to mediate the effector functions that are
encoded in the different C region genes and to be distrib-
uted throughout the body (1).
 
Even though the somatic hypermutation of antibody V
regions was first described in 1970, the mechanisms respon-
sible for its regulation, targeting, and biochemistry have
been remarkably elusive. This is especially surprising be-
cause the sequences of thousands of mutated H and L chain
V regions have been determined and the general character-
istics of the mutational process are known. The rate of mu-
tation of antibody V regions is estimated to be one million
times higher than the rate of mutation in most other genes,
with V regions accumulating 5–10 mutations during the
secondary antibody response. Somatic mutation begins a
few hundred bases downstream from the promoter of rear-
 
ranged V regions and continues for 
 
z
 
1.5 kb (2) but not
further downstream to the intronic enhancer and the con-
stant region. Mutations are largely single base changes, al-
though deletions and insertions occur (3). Transitions occur
more frequently than transversions, and hot spot motifs
such as RGYW (A/G, G, C/T, A/T) and its complemen-
tary sequence on the other strand are preferentially targeted.
Although mutations are targeted to both strands, there is
some controversy about whether there is strand bias (4).
Some of the cis-acting sequences responsible for the reg-
ulation and targeting of V region hypermutation have been
identified through deletion analysis of Ig transgenes. In ec-
topically integrated L chain transgenes and in endogenous
H chain genes in mice, promoters and enhancers that regu-
late transcription are required for mutation, although the
promoter and the V(D)J target for mutation and can be re-
placed by non-Ig elements without affecting the mutational
process (5). The requirement for transcriptional regulatory
elements has led to the belief that transcription, or at least
accessibility, is required for the activation of V region hy-
permutation (6).
Proteins that participate in V region mutation have been
sought by studying mice and humans that are genetically
defective in a wide variety of repair processes, including
those that are linked to transcription. It appears that tran-
scription-associated base and nucleotide excision repair is
not involved in V region mutation (7). However, mis-
match repair (MMR) does play a role, as V regions in mice
that lack the MutS homologue (MSH)2 and MSH6, as well
as postmeiotic segregation (PMS)2 and MutL homologue
(MLH)1 that act downstream from them, have mutations
mostly in G and C bases within hot spots, whereas almost
no mutations are seen in A and T (8, 9). This has led to the
suggestion that G and C are initially targeted for mutation
and that the mismatches created by those changes are then
recognized by the MMR proteins, which cause secondary
mutations in A and T through some error-prone process
(10). It has also been suggested that MMR proteins play a
more direct role in the primary mutational event (3, 11).
As V(D)J rearrangement, somatic V region mutation,
and isotype switching are all linked to transcription and
thought to require DNA breaks, many studies have sought
trans-acting proteins and biochemical mechanisms that
might be shared by these three processes. Even though
V(D)J rearrangement occurs early in B cell development in
primary lymphoid organs, whereas both isotype switching
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and somatic V region mutation occur later in the germinal
centers of secondary lymphoid organisms, there has been a
recurrent interest in whether the RAG1 and RAG2 endo-
nucleases could play a role in V region hypermutation.
This has been difficult to test because Ig expression and B
cell development is blocked in mice that are lacking these
enzymes. Even if B cells were provided with already rear-
ranged H and L chain genes, somatic mutation requires a T
cell–dependent response, but both TCRs and T cell devel-
opment are also blocked in mice that lack the RAG pro-
teins. In this issue, Bemark et al. (12) have overcome this
problem by creating 
 
Rag1
 
2
 
/
 
2
 
 mice that have rearranged Ig
and TCR transgenes. Although these mice are monoclonal
for both antibody and TCR, they develop Peyer’s patches
with germinal centers. The important observation is that V
region mutation occurs in the L chain transgenes of the
 
Rag1
 
2
 
/
 
2
 
 
 
mice. Though there may be some subtle differ-
ences, the frequency and characteristics of the mutations
were indistinguishable from the 
 
Rag1
 
1
 
/
 
1
 
 mice bearing the
same transgenes (12)
It seemed more likely that the DNA protein kinase cata-
lytic subunit (DNA-PK
 
cs
 
) might play a role in V region
mutation, as in addition to its role in V(D)J rearrangement,
it is required for isotype switching that occurs in the mi-
croenvironment of germinal center B cells at about the
same time as V region mutation. Although V region muta-
tion and isotype switching can occur independently, a
mechanistic relationship was suggested by the finding that
the MSH2 protein that recognizes single base pair mis-
matches in DNA was involved in both processes and might
even be targeting the same hot spot motifs (13, 14). In ad-
dition, as it has been suggested that double-stranded DNA
breaks that can recruit terminal deoxynucleotidyl trans-
ferase (TdT) occur during V region mutation (15), it
seemed possible that proteins such as DNA-PK
 
cs
 
 that are
involved in repairing such lesions might also play some role
in V region mutation. Using the same transgenic system
described above, Bemark et al. (12) have also shown that
SCID mice lacking DNA-PK
 
cs
 
 activity can carry out so-
matic V region mutation in an apparently normal manner.
This not only shows that DNA-PK
 
cs
 
 is not required for V
region mutation but also raises the possibility that double-
stranded DNA breaks are not required for the mutational
process (12).
A continuing examination of the basic characteristics of
V region mutation has led to suggestions for specific bio-
chemical mechanisms such as mutation associated with
transcriptional pausing (6), polymerase slippage (3), error-
prone polymerization recruited by MMR (10), or error-
prone reverse transcription (2). Within the last few months,
an unusual cytidine deaminase (AID) that resembles an
mRNA editing enzyme was found to be highly expressed
in germinal center B cells and to be required for isotype
switching (16, 17). Mice lacking AID and patients with
mutations in the gene encoding this enzyme have a 10-
fold, or perhaps greater, decrease in V region hypermuta-
tion. Although the mechanism of action of AID is unclear,
and V region mutation still seems to be occurring in mice
 
and humans with defects in this protein, these studies again
suggest that the mechanisms underlying V region mutation
and isotype switching may be related.
Thus, through a process of elimination and the identifi-
cation of some trans-acting proteins that are involved, it is
possible that we are beginning to close in on some of the
mechanisms that could play a role in V region mutation.
There is even reason to hope that we may be closer than
we think. Many of the studies described above invoke
some sort of error-prone process and thus harken back to
the suggestion by Brenner and Milstein in 1966 (18) that an
error-prone DNA polymerase must be involved in the
generation of antibody diversity. By studying a transgene
with an artificial substrate for mutation
 
, 
 
Bertocci et al. (19)
concluded that mutation resulted from nonreplicative er-
ror-prone short patch DNA synthesis, again pointing to a
central role for an error-prone polymerase. Unfortunately,
at that time, only a few error-prone DNA polymerases that
might contribute to the mutational process had been iden-
tified in animal cells. One prime candidate was pol 
 
b
 
,
which can fill small gaps in DNA and is quite error prone.
However, Esposito et al. (20) have shown that B cells lack-
ing pol 
 
b
 
 carry out normal V region mutation in vivo, thus
eliminating one more possibility.
Figure 1. A speculative mechanism for somatic V region hypermuta-
tion. I. An unusual cytidine deaminase might play a role in the introduc-
tion of abasic lesions (O) in DNA via conversion of C to U, followed by
the removal of the U by uracil glycosylase (UDG1). RGYW/WRCY
represent a hot spot template sequence (A/G, G, C/T, A/T), with a mu-
tation occurring most frequently opposite the G/C. II. A high-fidelity
processive replicative polymerase (pol d) stalls at the abasic lesion, dissoci-
ates, and is replaced by a promiscuous nonprocessive polymerase, e.g., pol
i (shown in sketch), or by some other errant polymerase. After transle-
sional synthesis resulting in a mutation opposite the lesion, pol i dissoci-
ates, and processive synthesis resumes with pol d. III. A subsequent round
of replication results in a mixed population of B cell clones, some mutated
and some not. Alternative mechanisms can be envisioned that do not in-
volve the introduction of a lesion. Instead, an undamaged DNA template
could be copied by a low-fidelity polymerase such as pol i, causing muta-
tions that are favored in the RGYW hot spot sequence. 
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Although only a few mammalian error-prone DNA
polymerases were known two years ago, recent studies in
bacteria, yeast, and animal cells (21) shed new light on a
class of enzymes that could be responsible for V region mu-
tation. These are members of the UmuC/DinB/Rev1/
Rad30 family of proteins that are required to replicate
damaged DNA and are also responsible for many spontane-
ous mutations in 
 
Escherichia coli
 
 and 
 
Saccharomyces cerevisiae
 
.
Recent biochemical studies reveal that most members of
the UmuC/DinB/Rev1/Rad30 family of DNA poly-
merases can be highly error prone when replicating normal
undamaged DNA while also exhibiting the ability to toler-
ate damaged bases in a DNA template. Whereas most
DNA polymerases stall when they encounter an aberrant
base, these remarkable polymerases bypass lesions in dam-
aged DNA by inserting one or a few bases across from the
template stand (Fig. 1). These enzymes lack editing func-
tions and, because they are relatively nonprocessive, they
have to be replaced by replicative polymerases to fully ex-
tend the DNA. In the last two years, human and mouse
homologues for this family have been identified based on
their homology with five sequence motifs that are con-
served in this family (22). The roles of these enzymes in
vivo and the details of their tissue and cellular expression
are largely unknown.
As additional members of this polymerase family such as
pol 
 
i
 
 have been characterized (23), it has been suggested
that they might play a role in V region mutation. We have
found that pol 
 
i
 
 is expressed in lymphoid tissue. A role for
pol 
 
i
 
 is also suggested by its preference for incorporating G
instead of A opposite T, creating transition mutations and
mutating A rather than T (23), both characteristics of V re-
gion mutation. Other new polymerases have been discov-
ered recently that are not members of the UmuC/DinB/
Rad30/Rev1 family. The identification and characteriza-
tion of pol 
 
z
 
 in yeast (24) and homologues in humans (25,
26) led Diaz et al. (27) to suggest that it might be playing a
role in V region mutation. In a model system using human
pol 
 
i
 
 and yeast pol 
 
z
 
, mismatches formed by pol 
 
i
 
 were ex-
tended by pol 
 
z
 
, and something akin to this could be oc-
curring in vivo
 
 
 
(28). It has also been suggested that pol 
 
m
 
,
which is homologous to TdT and like pol 
 
z
 
 is not a mem-
ber of the UmuC/DinB/Rev1/Rad30 family, might play a
role in V region mutation (29). Pol 
 
m
 
 can also carry out er-
ror-prone polymerization, and a large number of expressed
sequence tags come from cells of germinal center origin,
suggesting that it is highly expressed in B cells that are in-
volved in V region mutation.
Thus, there is now an increasing abundance of error-
prone DNA polymerases that, based on their expression
and biochemical properties, could individually or in com-
bination play a role in V region hypermutation. Even if
studies that are now underway in many laboratories reveal
that one or more of the errant polymerases plays a role in V
region hypermutation, it will still be essential to understand
how these molecules are targeted to Ig V regions at a par-
ticular stage in B cell differentiation. One possibility is that
the relevant enzymes are induced in cells that are about to
 
undergo V region mutation. They then might form a com-
plex with B cell–specific factors and be targeted by cis-act-
ing sequences to the Ig gene whose chromatin has been
modified to make it accessible to this complex. This seems
a likely possibility, as Bcl-6, which is also highly expressed
in germinal center cells, is subjected to the V region muta-
tional process (30, 31). As part of this process, the hot spots
in the Ig gene and in Bcl-6 may be damaged, for example
by the creation of abasic sites, and provide the signal for the
recruitment and targeting of a mutation complex that may
include pol 
 
i 
 
and pol 
 
m
 
 or other polymerases (Fig. 1). If
these low-fidelity polymerases are to play a role in somatic
hypermutation, it is unlikely that they act alone. For exam-
ple, in 
 
E. coli
 
, pol V acts in concert with Rec A, single-
stranded DNA binding protein, and the 
 
b
 
 processivity
binding clamp and 
 
g
 
 clamp loading protein (that are also
part of the replicative polymerase complex) to catalyze
translesional synthesis (32). In an analogous manner, pol 
 
i
 
or one of the other error-prone polymerases might interact
with B cell–induced factors that target these polymerases to
variable gene loci. The important message is that these
many error-prone DNA polymerases provide us with new
opportunities to identify the major players responsible for
V region hypermutation and then to see how they are reg-
ulated and targeted to the V region of Ig genes.
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